Seminar article
What is the best way to radiate the prostate in 2016?

https://doi.org/10.1016/j.urolonc.2016.06.002Get rights and content

Highlights

  • Intensity-modulated radiation therapy with image guidance is considered standard of care for definitive prostate cancer radiation therapy.

  • Brachytherapy is used as monotherapy for lower-risk patients whereas its combination with external beam radiation therapy is used for higher-risk patients.

  • Proton therapy has been shown to be safe and effective for the treatment of prostate cancer, but additional studies would be required to determine whether it leads to improvement in clinical outcomes compared to intensity-modulated radiation therapy.

  • Hypofractionated radiation therapy delivers larger daily radiation dose, reducing the overall treatment time and possibly cost, and it has been shown to be noninferior to conventional fractionation.

  • Stereotactic body radiation therapy is an extreme form of hypofractionation, delivering treatment in a total of 3 to 5 sessions, with growing evidence for its use in low- to intermediate-risk prostate cancer patients.

Abstract

Prostate cancer treatment with definitive radiation therapy (RT) has evolved dramatically in the past 2 decades. From the initial 2-dimensional planning using X-rays, advances in technology led to 3-dimensional conformal RT, which used computerized tomography-based planning. This has allowed delivery of higher doses of radiation to the prostate while reducing dose to the surrounding organs, resulting in improved cancer control. Today, intensity-modulated RT (IMRT) is considered standard, where radiation beams of different shapes and intensities can be delivered from a wide range of angles, thus further decreasing doses to normal organs and likely reducing treatment-related toxicity. In addition, image guidance ascertains the location of the prostate before daily treatment delivery.

Brachytherapy is the placement of radioactive seeds directly in the prostate, and has a long track record as a monotherapy for low-risk prostate cancer patients with excellent long-term cancer control and quality of life outcomes. Recent studies including several randomized trials support the use of brachytherapy in combination with external beam RT for higher-risk patients.

RT for prostate cancer continues to evolve. Proton therapy has a theoretical advantage over photons as it deposits most of the dose at a prescribed depth with a rapid dose fall-off thereafter; therefore it reduces some doses delivered to the bladder and rectum. Prospective studies have shown the safety and efficacy of proton therapy for prostate cancer, but whether it leads to improved patient outcomes compared to IMRT is unknown.

Hypofractionated RT delivers a larger dose of daily radiation compared to conventional IMRT, and thus reduces the overall treatment time and possibly cost. An extreme form of hypofractionation is stereotactic body radiation therapy where highly precise radiation is used and treatment is completed in a total of 4 to 5 sessions. These techniques take advantage of the biological characteristic of prostate cancer, which is more sensitive to larger radiation doses per fraction, and therefore could be more effective than conventional IMRT. Multiple randomized trials have demonstrated noninferiority of moderately hypofractionated RT compared to conventional fractionation. There is also a growing body of data demonstrating the safety and efficacy of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer.

Section snippets

Introduction: Historical perspective

Radiation therapy (RT) has a long track record as a curative treatment modality for localized prostate cancer. Overall, 2 large randomized trials compared androgen deprivation therapy (ADT) vs. ADT plus RT for patients with high-risk/locally advanced prostate cancer, and both showed that RT improves overall survival by an absolute difference of 8% to 10% [1], [2]. Radiation delivered in the form of X-rays or protons causes DNA damage, which is preferentially repaired in the normal tissue

Current standards

In addition to the decreased rates of toxicities, the use of more conformal radiation treatment techniques also enabled safer delivery of higher doses of radiation to the prostate. At least 5 randomized trials have compared traditional radiation doses (64–70 Gy) to dose-escalated RT (74–80 Gy) [11], [12], [13], [14], [15], and all consistently demonstrated improved disease-free survival with escalated doses, and this has become current standard of care (Table 1). By 2011, 90% of patients in the

Brachytherapy

Brachytherapy involves inserting radioactive sources directly into the prostate, and has been used for the treatment of prostate cancer since the 1920s. Low dose rate brachytherapy consists of placing permanent seed implants (either Iodine-125 or Pallidium-103) in the prostate, whereas high dose rate brachytherapy entails temporary insertion of high energy radioactive isotope such as Iridium-192. The direct delivery of radioactive sources into the prostate significantly reduces radiation doses

Proton therapy

Proton therapy uses a different radiation particle (protons) than X-ray (photon radiation). A heavy, charged particle such as a proton deposits most of its dose at a prescribed depth in the body with a rapid dose fall-off beyond this point; this phenomenon is called the “Bragg peak.” This means that proton therapy can reduce radiation dose delivered to tissues beyond the target compared to photon radiation. Although proton and photon particles are deemed to be similarly effective in prostate

Conclusion

Definitive RT for prostate cancer has evolved dramatically in the past 2 decades. Once treated with a few fields based on the patient׳s bony anatomy on X-ray, prostate cancer patients now receive higher doses of radiation using IMRT with image guidance. The “best” way to deliver radiation for prostate cancer continues to evolve through clinical studies including many randomized trials. For low-risk prostate cancer patients, active surveillance is the recommended disease management strategy in

References (84)

  • D.P. Dearnaley et al.

    Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial

    Lancet Oncol

    (2014)
  • V. Beckendorf et al.

    70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial

    Int J Radiat Oncol Biol Phys

    (2011)
  • A. Al-Mamgani et al.

    Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer

    Int J Radiat Oncol Biol Phys

    (2008)
  • S. Swisher-McClure et al.

    Increasing use of dose-escalated external beam radiation therapy for men with nonmetastatic prostate cancer

    Int J Radiat Oncol Biol Phys

    (2014)
  • D.P. Dearnaley et al.

    Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

    Lancet Oncol

    (2007)
  • C.C. Ling et al.

    Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with dynamic multileaf collimation

    Int J Radiat Oncol Biol Phys

    (1996)
  • G. Bauman et al.

    Expert Panel MotII. Intensity-modulated radiotherapy in the treatment of prostate cancer

    Clin Oncol (R Coll Radiol)

    (2012)
  • O. Cahlon et al.

    Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes

    Int J Radiat Oncol Biol Phys

    (2008)
  • A. Al-Mamgani et al.

    Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer

    Int J Radiat Oncol Biol Phys

    (2009)
  • M.J. Zelefsky et al.

    Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer

    Radiother Oncol

    (2000)
  • M.J. Zelefsky et al.

    Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer

    Int J Radiat Oncol Biol Phys

    (2008)
  • U.A. van der Heide et al.

    Analysis of fiducial marker-based position verification in the external beam radiotherapy of patients with prostate cancer

    Radiother Oncol

    (2007)
  • K.M. Langen et al.

    Initial experience with megavoltage (MV) CT guidance for daily prostate alignments

    Int J Radiat Oncol Biol Phys

    (2005)
  • T.R. Willoughby et al.

    Target localization and real-time tracking using the Calypso 4D localization system in patients with localized prostate cancer

    Int J Radiat Oncol Biol Phys

    (2006)
  • R.C. Wortel et al.

    Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients

    Int J Radiat Oncol Biol Phys

    (2015)
  • A. Sandhu et al.

    Prostate bed localization with image-guided approach using on-board imaging: reporting acute toxicity and implications for radiation therapy planning following prostatectomy

    Radiother Oncol

    (2008)
  • H.T. Chung et al.

    Does image-guided radiotherapy improve toxicity profile in whole pelvic-treated high-risk prostate cancer? Comparison between IG-IMRT and IMRT

    Int J Radiat Oncol Biol Phys

    (2009)
  • M.J. Zelefsky et al.

    Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer

    Int J Radiat Oncol Biol Phys

    (2012)
  • P.J. Hoskin et al.

    Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer

    Radiother Oncol

    (2012)
  • A. Trofimov et al.

    Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison

    Int J Radiat Oncol Biol Phys

    (2007)
  • C. Vargas et al.

    Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer

    Int J Radiat Oncol Biol Phys

    (2008)
  • J.J. Coen et al.

    Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II study 03-12

    Int J Radiat Oncol Biol Phys

    (2011)
  • K. Nihei et al.

    Multi-institutional phase II study of proton beam therapy for organ-confined prostate cancer focusing on the incidence of late rectal toxicities

    Int J Radiat Oncol Biol Phys

    (2011)
  • N.P. Mendenhall et al.

    Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer

    Int J Radiat Oncol Biol Phys

    (2014)
  • J.D. Slater et al.

    Proton therapy for prostate cancer: the initial Loma Linda University experience

    Int J Radiat Oncol Biol Phys

    (2004)
  • S. Kim et al.

    Late gastrointestinal toxicities following radiation therapy for prostate cancer

    Eur Urol

    (2011)
  • D.J. Brenner et al.

    Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue

    Int J Radiat Oncol Biol Phys

    (2002)
  • J. Fowler et al.

    Is alpha/beta for prostate tumors really low?

    Int J Radiat Oncol Biol Phys

    (2001)
  • G. Arcangeli et al.

    A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer

    Int J Radiat Oncol Biol Phys

    (2010)
  • S. Arcangeli et al.

    Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer

    Int J Radiat Oncol Biol Phys

    (2012)
  • D.W. Kim et al.

    Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer

    Int J Radiat Oncol Biol Phys

    (2014)
  • B.L. Madsen et al.

    Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results

    Int J Radiat Oncol Biol Phys

    (2007)
  • Cited by (33)

    • HDR brachytherapy boost using MR-only workflow for intermediate- and high-risk prostate cancer: 8-year results of a pilot study

      2021, Brachytherapy
      Citation Excerpt :

      Existing evidence shows that biochemical control rates are improved if the delivered dose to the prostate gland is increased (1).

    • Factors Influencing Noncompletion of Radiation Therapy Among Men With Localized Prostate Cancer

      2021, International Journal of Radiation Oncology Biology Physics
      Citation Excerpt :

      Greater understanding of predictors of treatment noncompletion may therefore nuance how providers guide shared decision-making in an effort to promote equity. Certain fractionation schedules for prostate cancer, including stereotactic body radiation therapy (SBRT), are undergoing active investigation; these fractionation schedules may provide acceptable tumor control compared with standard regimens.6-9 Importantly, rates of treatment noncompletion for different fractionation schedules merit further study.

    • Sexual Function in Patients Treated With Stereotactic Radiotherapy For Prostate Cancer: A Systematic Review of the Current Evidence

      2019, Journal of Sexual Medicine
      Citation Excerpt :

      An enormous benefit of SBRT is the considerable reduction of treatment course duration: SBRT can be completed within 1 week, whereas the conventionally fractionated EBRT regimens are generally delivered in 6–8 weeks.1 At present, no treatment modality has proven to be superior in terms of long-term efficacy, and the choice of the therapeutic option is often influenced by the expected balance between efficacy and risk of adverse events.5 In particular, sexual function can be severely affected by all traditional prostate cancer treatment modalities6 and represents an important source of distress for patients.

    • Patient-reported Quality of Life Following Stereotactic Body Radiotherapy and Conventionally Fractionated External Beam Radiotherapy Compared with Active Surveillance Among Men with Localized Prostate Cancer

      2019, European Urology
      Citation Excerpt :

      These results are consistent with the data reported in Table 2. There is intense research interest in shortening the RT course in prostate cancer due to the improved patient convenience of fewer treatments, associated cost savings, and potential radiobiological advantages of delivering high doses per fraction [16]. Nine randomized trials have been published comparing conventionally fractionated RT (8–9 wk) with moderately hypofractionated RT (4–5 wk), demonstrating similar cancer-control outcomes, although some trials have shown increased toxicity from hypofractionation [17].

    • Prostate MR Imaging for Posttreatment Evaluation and Recurrence

      2018, Urologic Clinics of North America
      Citation Excerpt :

      The seeds internally give off radiation to treat the prostate, and this is best used for low-grade disease and in smaller prostates. For higher-grade disease, brachytherapy may be combined with EBRT for improved cancer treatment.43 All RT may be combined with hormonal therapy in an effort to shrink the prostate for maximal treatment efficacy.11

    View all citing articles on Scopus
    View full text